About

Rainbow Childrens Medicare operates pediatric-focused hospital services in India with a market cap of ₹14,851.89 Cr. The company demonstrates strong operational metrics with 31.95% operating margins and zero debt, positioning it as a specialized healthcare services provider in India's children's healthcare segment.

Face value: ₹10

Market cap

₹13,003 Cr

P/E

45.6×

P/B

7.9×

Dividend yield

0.3%

ROE

17.9%

ROCE

18.2%

Debt / equity

0

OPM

32%

EPS (TTM)

₹28.1

Book value

₹162.3

52-week high

₹1,598.6

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Valuation premium: PE of 52.04 offers limited downside protection if earnings disappoint; verify if 31.95% margins and 17.86% ROE can sustain expected growth
Market skepticism: 1-year return of -1.44% despite strong fundamentals suggests unaddressed concerns; clarify investor worries around growth, competition, or sector headwinds
Operational variability: Quarterly OPM ranges from 27.93% to 34.45%; verify whether this reflects seasonality, capacity utilization, or underlying inconsistency
Scale and concentration: As a specialized operator, verify number of centers, bed capacity, and geographic concentration as potential constraints on growth

Generated analysis · source review pending

Growth drivers

Margins of 31.95% suggest pricing power or operational efficiency in pediatric healthcare; verify if this advantage sustains as scale increases
Zero debt (D/E = 0) enables growth investment through leverage or organic reinvestment; verify planned capex and expansion roadmap
Quarterly margin consistency (27.93–34.45%) indicates structural efficiency rather than one-time gains; verify if revenue can scale without margin compression
ROE of 17.86% on a zero-debt balance sheet suggests room to invest for growth; verify management's capital allocation and expansion priorities

Generated analysis · source review pending

₹1,279.8-6%1Y

Beta

0.59

Damps index moves

Volatility (1y)

22.8%

Annualised, daily returns

RSI (14)

13.9

Oversold territory

Rel. strength (1y)

-16.4%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Strong return on equity of 18.1% (3-yr avg)
+Healthy operating margin of 32%
+Profit CAGR of 47.4% over the last 5 years
+Revenue CAGR of 21.2% over the last 5 years
+Almost debt-free (debt/equity 0)

Cons

No red flags triggered.

Research score

Structured signal from quality, growth, valuation and momentum.

44/100

Business quality: 64
Growth: 61
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY SMALLCAP 250 NIFTY MIDSMALLCAP 400 NIFTY 500 NIFTY TOTAL MARKET

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Max Healthcare Institute LimitedMAXHEALTHMAXHEALTH	₹91,573 Cr	₹95,052 Cr	₹8,712 Cr	₹2,318 Cr	26.8%	₹1,457 Cr	17.2%	13.8%	14.3%	-110
Manipal Health Enterprises LimitedMANIPALHOSMANIPALHOS	₹91,552 Cr	₹1,02,105 Cr	₹10,336 Cr	₹2,611 Cr	25.3%	₹917 Cr	8.9%	12.5%	12.8%	38
Fortis Healthcare LimitedFORTISFORTIS	₹59,268 Cr	₹62,140 Cr	₹9,506 Cr	₹2,131 Cr	22.8%	₹1,048 Cr	11.7%	13%	11.1%	-99
Aster Dm Healthcare LimitedASTERDMASTERDM	₹36,728 Cr	₹37,429 Cr	₹4,876 Cr	₹958 Cr	19.4%	₹319 Cr	9.2%	11.9%	9.7%	-112
Global Health LimitedMEDANTAMEDANTA	₹36,498 Cr	₹37,688 Cr	₹4,683 Cr	₹979 Cr	20.8%	₹556 Cr	12.6%	16.9%	15.1%	-26
Narayana Hrudayalaya Ltd.NHNH	₹35,594 Cr	₹40,460 Cr	₹9,072 Cr	₹1,749 Cr	20.5%	₹816 Cr	10.2%	15.1%	19.7%	-181
Krishna Institute Of Medical Sciences LimitedKIMSKIMS	₹29,457 Cr	₹32,701 Cr	₹4,213 Cr	₹833 Cr	20.5%	₹205 Cr	6.2%	9.5%	11%	-50
Dr. Agarwal's Health Care LimitedAGARWALEYEAGARWALEYE	₹15,420 Cr	₹15,578 Cr	₹2,207 Cr	₹612 Cr	27.4%	₹148 Cr	8.1%	10.1%	6.8%	-76
Rainbow Childrens Medicare LimitedRAINBOWRAINBOW	₹13,003 Cr	₹13,003 Cr	₹1,820 Cr	₹575 Cr	32%	₹285 Cr	16.5%	18.2%	17.9%	-73
Park Medi World LimitedPARKHOSPSPARKHOSPS	₹11,696 Cr	₹11,924 Cr	₹1,679 Cr	₹444 Cr	26.5%	₹258 Cr	16.3%	21.4%	16.7%	-2
Healthcare Global Enterprises LimitedHCGHCG	₹9,984 Cr	₹10,895 Cr	₹2,627 Cr	₹480 Cr	18.3%	₹23 Cr	0.9%	9.1%	1.2%	-93
Yatharth Hospital & Trauma Care Services LimitedYATHARTHYATHARTH	₹9,965 Cr	₹10,218 Cr	₹1,334 Cr	₹310 Cr	24.2%	₹174 Cr	14.1%	12.3%	10%	-26

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	650	974	1,174	1,297	1,516	1,703
COGS	—	195	158	165	195	227
Gross profit	—	779	1,015	1,132	1,321	1,476
	487	474	619	703	831	932
	163	305	396	429	490	544
OPM %	25.1%	31.3%	33.8%	33.1%	32.3%	32%
Depreciation	73	83	90	112	138	151
Interest	44	53	55	59	72	78
	10	19	31	37	51	42
Profit before tax	56	187	282	295	330	358
Tax	16	49	69	77	86	77
Tax %	29%	26%	24.6%	26%	26%	21.4%
	40	139	212	218	244	282
PAT margin %	6.1%	14.2%	18.1%	16.8%	16.1%	16.5%
EPS (₹)	4.3	14.8	20.9	21.4	24	27.4
EPS adjusted (₹)	7.3	13.2	20.8	21.4	24	27.4
	0%	13.6%	14.4%	14%	12.5%	12.8%
Annual report	—	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	55	105	102	102	102	102
Reserves	391	498	958	1,157	1,367	1,547
Minority interest	2	3	5	6	7	16
	48	42	0	0	0	0
	585	648	711	905	902	1,111
Total equity & liabilities	1,081	1,296	1,776	2,170	2,377	2,775
	403	423	931	1,253	1,398	1,756
CWIP	29	5	21	14	28	76
Investments	18	22	58	308	571	405
	631	846	766	596	380	539
Total assets	1,081	1,296	1,776	2,170	2,377	2,775

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	80%	86.5%	87.3%	87.1%	86.7%
EBITDA margin %	25.1%	31.3%	33.8%	33.1%	32.3%	32%
EBIT margin %	13.8%	22.8%	26.1%	24.4%	23.2%	23.1%
PAT margin %	6.1%	14.2%	18.1%	16.8%	16.1%	16.5%
Working capital
Receivable days	25	15	18	20	19	22
Inventory days	8	28	43	53	52	67
Payable days	—	—	195	180	170	162
NWC days	—	—	-133	-107	-100	-73
Leverage
Current ratio	1.61	2.32	3.35	4.16	5.53	3.59
Debt to EBITDA	0.29	0.14	0	0	0	0
Debt to equity	0.11	0.07	0	0	0	0
Interest coverage	2.3	4.5	6.1	6	5.6	5.6
Asset turnover	0.6	0.75	0.66	0.6	0.64	0.61
Return ratios
Return on assets %	3.7%	10.7%	12%	10.1%	10.3%	10.1%
Return on capital employed %	10.4%	22.6%	24%	19.4%	19%	18.2%
Return on equity %	8.9%	23%	20%	17.3%	16.6%	17.1%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	49.83%	49.83%	49.83%	49.88%	49.85%	49.85%	49.85%	49.85%	49.85%	49.84%	49.84%	49.84%
	21.63%	22.32%	24.04%	24.78%	25.11%	25.12%	23.69%	23.59%	21.85%	19.23%	17.24%	16.03%
	15.4%	15.62%	14.76%	13.8%	13.83%	13.87%	15.31%	15.44%	17.46%	19.49%	21.13%	22.56%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	13.14%	12.23%	11.37%	11.54%	11.21%	11.16%	11.15%	11.12%	10.84%	11.4%	11.67%	11.39%
No. of shareholders	—	—	—	—	—	—	—	—	81,134	88,809	88,561	89,305

Promoter holding up 0.01 percentage points since Sep 2023.

12 deals · 5 Dec 2022 – 15 Sept 2023

Date	Client	Type	Venue	Side	Quantity	Price	Value
15 Sept 2023	BNP PARIBAS ARBITRAGE	Bulk	NSE	Sell	6,55,246	₹1,023.22	₹67.05 Cr
15 Sept 2023	BNP PARIBAS ARBITRAGE	Bulk	NSE	Buy	1,568	₹1,025.22	₹0.16 Cr
5 Dec 2022	CDC GROUP PLC	Bulk	NSE	Sell	96,32,876	₹735.55	₹708.55 Cr
5 Dec 2022	CDC INDIA OPPORTUNITIES LIMITED	Bulk	NSE	Sell	50,33,236	₹735.00	₹369.94 Cr
5 Dec 2022	STICHTING DEPOSITARY APG EMERGING MARKETS EQUITY POOL	Bulk	NSE	Buy	15,11,300	₹735.00	₹111.08 Cr
5 Dec 2022	GOVERNMENT OF SINGAPORE	Bulk	NSE	Buy	14,46,185	₹735.00	₹106.29 Cr
5 Dec 2022	ICICI PRUDENTIAL MUTUAL FUND	Bulk	NSE	Buy	12,53,750	₹735.00	₹92.15 Cr
5 Dec 2022	ABU DHABI INVESTMENT AUTHORITY	Bulk	NSE	Buy	9,00,000	₹741.25	₹66.71 Cr
5 Dec 2022	STICHTING DEPOSITARY APG EMERGING MARKETS EQUITY POOL	Bulk	NSE	Buy	7,45,200	₹735.00	₹54.77 Cr
5 Dec 2022	INDIA ACORN ICAV - ASHOKA INDIA OPPORTUNITIES FUND	Bulk	NSE	Buy	7,22,000	₹735.00	₹53.07 Cr

1–10 of 12

1 / 2

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Ramesh KancharlaExecutive Director-Chairperson-MD
Mr. Ch Dinesh KumarExecutive Director
Mr. Adarsh KancharlaNon-Executive - Non Independent Director
Mr. Anil DhawanNon-Executive - Independent Director
Mr. Aluri Srinivasa RaoNon-Executive - Independent Director
Ms. Sundari R PisupatiNon-Executive - Independent Director
Mr. Santanu MukherjeeNon-Executive - Independent Director
Mr. Vikas MaheshwariChief Financial Officer
Ms. Shreya MitraCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

65

across 12 fund houses

Held by these funds

15.31%

of the company's equity

All mutual funds

18.53%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

65 schemes · 12 fund houses

		Shares
Large & Mid Cap Fund	ICICI Prudential Mutual Fund	24.46 L	346	1.03%	2.407%	-0
Small Cap Fund	DSP Mutual Fund	15.37 L	217.43	1%	1.513%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	13.85 L	195.93	2.4%	1.363%	+35,027
Small Cap Fund	Axis Mutual Fund	10.63 L	150.43	0.48%	1.047%	-0
Flexi Cap Fund	DSP Mutual Fund	9.56 L	135.22	1.08%	0.941%	-0
SMALL CAP FUND	Nippon India Mutual Fund	7.85 L	111.06	0.13%	0.773%	-0
Aggressive Hybrid Fund	DSP Mutual Fund	7.7 L	108.89	0.93%	0.758%	-0
Healthcare FundNEW	ICICI Prudential Mutual Fund	6.74 L	95.32	1.36%	0.663%	—

1–8 of 65

1 / 9

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

5

Credit ratings

2

Investor Presentation and earnings call

5

Jul 2026TranscriptAI SummaryPPT REC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

5

Final dividend21 Jul 2026 · ex-date₹3.5
Final dividend27 Jun 2025 · ex-date₹3
Final dividend23 Jul 2024 · ex-date₹3
Final dividend22 Jun 2023 · ex-date₹3
Final dividend7 Sept 2022 · ex-date₹2

1

Board meeting to consider results30 Jul 2026

1

Earnings call31 Jul 2026call

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

32 announcementsExport CSV

31 Jul 2026, 12:09 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

30 Jul 2026, 5:39 pmCompany Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release / Media Release PDF

30 Jul 2026, 5:34 pmCompany Update

Announcement under Regulation 30 (LODR)-Investor Presentation

Investor Presentation PDF

30 Jul 2026, 5:06 pmCompany Update

Intimation Regarding Grant Of Options Under Employee Stock Option Scheme 2025

General PDF

30 Jul 2026, 4:39 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

30 Jul 2026, 4:31 pmBoard Meeting

Board Meeting Outcome for Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended June 30, 2026

Outcome of Board Meeting PDF

30 Jul 2026, 4:27 pmResult

Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended June 30, 2026

Financial Results PDF

29 Jul 2026, 10:26 pmCompany Update

Intimation For Capacity Addition

General PDF

Date	Category	Subject	Filing
31 Jul 2026, 12:09 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
30 Jul 2026, 5:39 pm	Company Update Press Release / Media Release	Announcement under Regulation 30 (LODR)-Press Release / Media Release

Loading announcements…

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	143	224	327	321	396	420
	-83	-175	-465	-226	-268	-259
	-61	-44	143	-102	-118	-147
Net cash flow	-1	4	5	-7	10	14
Free cash flow	—	162	186	-32	250	203
CFO / Operating profit %	87.6%	73.4%	82.6%	74.9%	80.8%	77.1%

Rainbow Childrens Medicare Limited

Rainbow Childrens Medicare Limited

About

Key insights

Key risks

Growth drivers

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Dividends5

Board meetings1

Other corporate actions1

Announcements

Not in the F&O segment

Dividends5

Board meetings1

Other corporate actions1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

5

1

1

5

1

1